Abstract
T he clinical effi cacy of highly active antiretroviral therapy (HAART) in children has been well documented in the developed countries, although most of the regimens are Protease Inhibitor (PI) based which are too expensive. To circumvent this problem World Health Organization (WHO) has recommended NonNucleotide Reverse Transcriptase Inhibitor (NNRTI) based regimen for resource-limited countries 1 . There are several reports on effi cacy of these non-PI based regimens in adults 2, 3, 4 and children 5, 6, 7, 8, 9, 10, 11 but the data on Indian children is still limited 12, 13, 14 .
This observational retrospective analysis describes the clinical and immunologic effects of HAART in treatment -naïve, HIV infected Indian children with WHO prequalifi ed fi rst line regimens in a tertiary care hospital in north India.
Materials and methods
HIV-1 naïve infected children on HAART for a period of six or more months were included. All children were on fi rst line WHO prequalifi ed fi xed-dose combinations (FDC) tablets of HAART provided by the National AIDS To correct for the effect of the natural decline of CD4 cells with age, age-adjusted CD4 T-cell ratios were calculated by dividing the counts by the median for an age-matched healthy control group 17 . Growth was analyzed by serial Z scores of weight, height and BMI. Z scores were calculated using the program Nutstat, which is part of Epi Info (CDC, Atlanta). Wilcoxan's rank-sum test with Bonferroni modifi cation was used to compute and evaluate the magnitude of change in CD 4 counts, percentages, ratios and anthropometric Z scores compared with baseline. Statistical signifi cance was considered as P <0.05 and all tests were two sided. Data were analysed with SPSS 13 (SPSS, Chicago, IL).
Results
Over a three years period (from 2005-2008) , 130 children (85 boys, 45 girls) were diagnosed to have HIV-1 infection. HAART was started in 35 children, of these 30 children (23 boys, 7 girls) had a follow up of greater than six months. Further details are described for these 30 children only.
Baseline characteristics
Baseline characteristics of children are summarised in Table 1 . Six (20%) children were between one to three years, nine (30%) between three to fi ve years, and 15 (50%) >5 years of age. All patients were pre-pubertal. Twenty seven children had acquired HIV perinatally, with two having acquired through contaminated blood transfusions and one with mode of acquisition unknown.
Twenty seven of 30 children included were on d4T/3TC/ NVP and rest on ZDV/3TC/NVP. The median duration on HAART was 18 months (Interquartile [IQR]: 6-24). All patients took more than 95% of prescribed medications during the study period. None of the children had received any anti-retroviral drug for prevention of perinatal transmission. No additional nutritional supplements were provided.
Clinical response and adverse drug events
Three new staging were observed during the fi rst six months of HAART (one case each of herpes zoster involving only the skin; oral candidiasis and cryptosporidium diarrhoea) but no new events were observed thereafter. During the 36 months of follow up one patient was lost to follow up due to unknown reasons. There have been no deaths in the study population. One patient developed immunological failure without clinical failure and shifted to second line drugs.
Four subjects had grade 2 and one subject had grade 3 signs or symptoms. Two subjects had grade 2 nausea and vomiting during the fi rst week on the regimen, which resolved without intervention. Another two subjects had grade 2 rash, which subsided spontaneously. One subject had a grade 3 rash in the fi rst week of therapy that led to change of study medication. Rest no other signifi cant adverse drug reactions were observed.
Serial six monthly anthropometric Z scores are shown in Table 2 and Figure 1 . The WAZ and BMIZ showed a statistically signifi cant improvement on follow up. On the contrary there was no signifi cant improvement in linear growth velocity with a consequent loss in serial HAZ.
Immunological response
There were eight (27%) children with a baseline CD4 % < 5%, 19 (63%) with CD4% of 6-15% and three (10%) with CD4% of >15%. The median CD4 T-cell count, percentage and age-adjusted CD4 T-cell ratios demonstrated a statistically signifi cant increase during the 36 months of treatment (Fig 2A, 2B and Table III ). In addition, the rate of CD4 cell increase was greater during the fi rst 18-24 months of therapy and plateued subsequently (Fig 2B) . Stratifi ed analysis based on baseline CD T cell percentages show that even patients with a baseline CD4 % of <5% achieved percentage of >25% at 18-24 months and maintained it subsequently at that level as also observed in children with CD4 % of 5-15 %. Children with a baseline CD 4% of > 15 % also showed signifi cant rise in percentages and reached a median CD 4% of 38.42 % at 18 months, 49.07 % at 24 months and 45.49 % at 30 months of HAART ( Fig  2B) . immunological failure was observed. No signifi cant new staging events were observed after six months of initiation of HAART. Statistically signifi cant and sustained increase in CD4 T-cell counts, percentages and ratios were observed. Although, even patients with a baseline CD4 % of <5% achieved percentage of around 25% at 18-24 months of HAART and maintained it subsequently, the sub group of patients with a baseline CD 4% of >15 % achieved much higher median CD 4% although the number of children in this subgroup was small. Data on tolerability of HAART in Indian children are limited, but we observed no unexpected adverse events that led to withdrawal or modifi cation of treatment during follow up.
Signifi cant increase in the WAZ and BMIZ were observed. The reason why there was no signifi cant increase in the linear height velocity is unclear in our patients. HAART restores or preserves growth in most 17, 18, 19, 20 , but not all studies 21 . Possible reasons could include virological failure despite sustained rise in CD 4% or endocrine abnormalities such as hypothyroidism, growth hormone defi ciency, low IGF-1/IGFBP3 and adrenal dysfunction 22, 23, 24, 25, 26 . This subgroup of patients would require detailed endocrine evaluation after testing for viral loads. It has been shown that height velocity is more closely related to HIV disease progression than weight velocity and should be incorporated as a composite end point for ART clinical trials in HIVinfected children 27 .
Limitations of our study include small cohort size with a variable period of follow-up, unicenteric, and disproportion ately smaller number of patients in the ZDV/3TC/NVP arm. Disproportionately large number of older children, who are slow progressors, could also be a confounder explaining excellent response to HAART. Studies in a larger cohort including younger children with a longer follow-up period are needed to determine the duration of the clinical, virological, and immunological responses. Viral loads could not be determined due to poor availability and fi nancial constraints.
Conclusion
Despite these limitations, our study demonstrates the long-term feasibility; effectiveness and tolerability of NNRTI-based HAART regi mens in antiretroviral-naive, HIV-infected children in a resource-limited setting.
The results showed an overall excellent clinical and immunological response to HAART despite initiation of treatment in advanced stages and comparable to other studies with no major adverse events. NNRTI based HAART regimens can be continued in NACO/ WHO scale up programmes at present.
